MX2 and HIV-1 Restriction
Publisher
Springer New York
Reference38 articles.
1. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis. 2010;201(11):1686–96. 2. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O’Doherty U, Kostman J, Montaner LJ. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013;207(2):213–22. 3. Bishop KN, Mortuza GB, Howell S, Yap MW, Stoye JP, Taylor IA. Characterization of an amino-terminal dimerization domain from retroviral restriction factor Fv1. J Virol. 2006;80(16):8225–35. 4. Buffone C, Schulte B, Opp S, Diaz-Griffero F. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction. J Virol. 2015;89:3285–94. 5. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, Strouvelle VP, Zang TM, Willett BJ, Boutell C, Bieniasz PD, Wilson SJ. Host and viral determinants of Mx2 antiretroviral activity. J Virol. 2014;88(14):7738–52.
|
|